Ensysce Biosciences (ENSC) Payables (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Payables of $3.6 million for Q4 2025, up 115.48% year-over-year from $1.7 million in Q4 2024, and up 319.93% quarter-over-quarter from $851160.0 in Q3 2025.
Ensysce Biosciences (ENSC) Payables (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Payables for 9 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Payables rose 115.48% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (up 115.48% YoY), while the FY2025 annual figure was $3.6 million, up 115.48% from the prior year.
- Payables climbed to $3.6 million in Q4 2025 per ENSC's latest filing, from $851160.0 in the prior quarter.
- Across five years, Payables topped out at $13.0 million in Q4 2021 and bottomed at $319180.0 in Q1 2021.
- Historically, Payables has averaged $3.7 million across 5 years, with a median of $2.0 million in 2023.
- Annual changes were most pronounced in 2021 — Payables slumped 90.87% — and 2022, when it soared 2103.36%.
- Ensysce Biosciences' Payables stood at $13.0 million in 2021, then plunged by 44.74% to $7.2 million in 2022, then sank by 61.3% to $2.8 million in 2023, then plunged by 40.56% to $1.7 million in 2024, then surged by 115.48% to $3.6 million in 2025.
- Business Quant data shows ENSC's Payables at $3.6 million in Q4 2025, $851160.0 in Q3 2025, and $1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.57 Mn |
| Sep 30, 2025 | 851,160.00 |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 872,678.00 |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 936,434.00 |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 7.21 Mn |
| Sep 30, 2022 | 8.84 Mn |
| Jun 30, 2022 | 11.05 Mn |
| Mar 31, 2022 | 7.03 Mn |
| Dec 31, 2021 | 13.05 Mn |
| Sep 30, 2021 | 3.27 Mn |
| Jun 30, 2021 | 3.14 Mn |
| Mar 31, 2021 | 319,180.00 |